G. Xiao

发表

Variability in P-Glycoprotein Inhibitory Potency (IC50) Using Various in Vitro Experimental Systems: Implications for Universal Digoxin Drug-Drug Interaction Risk Assessment Decision Criteria

M. Jamei, X. Chu, K. Hillgren, 2013, Drug Metabolism and Disposition.

Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study

W. Humphreys, X. Chu, Caroline A. Lee, 2018, Drug Metabolism and Disposition.

Localization of human equilibrative nucleoside transporters, hENT1 and hENT2, in renal epithelial cells.

L. Mangravite, K. Giacomini, G. Xiao, 2003, American journal of physiology. Renal physiology.

A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans

L. Lesko, I. Nestorov, H. Naik, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

A Comparison of Total and Plasma Membrane Abundance of Transporters in Suspended, Plated, Sandwich-Cultured Human Hepatocytes Versus Human Liver Tissue Using Quantitative Targeted Proteomics and Cell Surface Biotinylation

S. Heyward, W. Humphreys, X. Chu, 2019, Drug Metabolism and Disposition.

Ontogeny of Hepatic Drug Transporters as Quantified by LC‐MS/MS Proteomics

X. Chu, R. Evers, A. Gaedigk, 2016, Clinical pharmacology and therapeutics.

Cerebrospinal Fluid Can Be Used as a Surrogate to Assess Brain Exposures of Breast Cancer Resistance Protein and P-Glycoprotein Substrates

E. Sands, G. Xiao, L. Gan, 2012, Drug Metabolism and Disposition.

PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling

Jie Li, Sihua Wang, Jun Liu, 2019, Oncoimmunology.

In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia

N. Dedic, G. Xiao, K. Koblan, 2022, Pharmaceutical Research.

Assessment of drug metabolism enzyme and transporter pharmacogenetics in drug discovery and early development: perspectives of the I-PWG.

R. Evers, L. Tremaine, R. de Kanter, 2016, Pharmacogenomics.

Current Approaches for Absorption, Distribution, Metabolism, and Excretion Characterization of Antibody-Drug Conjugates: An Industry White Paper

D. Rock, Michaela Bairlein, A. Kamath, 2016, Drug Metabolism and Disposition.

Current Approaches for Predicting Human PK for Small Molecule Development Candidates: Findings from the IQ Human PK Prediction Working Group Survey

A. Reichel, P. Marathe, G. Xiao, 2022, The AAPS Journal.

Design, synthesis, and biological evaluation of pyrazolopyrimidine-sulfonamides as potent multiple-mitotic kinase (MMK) inhibitors (part I).

L. Silvian, D. Aivazian, Lin Zhang, 2011, Bioorganic & medicinal chemistry letters.

Comparison of species differences of P-glycoproteins in beagle dog, rhesus monkey, and human using Atpase activity assays.

C. Xia, G. Xiao, L. Gan, 2006, Molecular pharmaceutics.

Design, synthesis and identification of novel, orally bioavailable non-covalent Nrf2 activators.

I. Enyedy, G. Xiao, B. Lucas, 2019, Bioorganic & medicinal chemistry letters.

Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis

G. Xiao, Jiabao Liang, Y. Kong, 2021, Turkish journal of medical sciences.

Fampridine is a Substrate and Inhibitor of Human OCT2, but not of Human MATE1, or MATE2K

G. Xiao, L. Gan, C. Boiselle, 2018, Pharmaceutical Research.

Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions

Sophie P. Chung, Shibing Deng, M. Jamei, 2013, Drug Metabolism and Disposition.

DMD050542 1367..1374

Sophie P. Chung, Shibing Deng, M. Jamei, 2013 .

Interindividual and Regional Variability in Drug Transporter Abundance at the Human Blood–Brain Barrier Measured by Quantitative Targeted Proteomics

Bhagwat Prasad, Yurong Lai, Jashvant D Unadkat, 2019, Clinical pharmacology and therapeutics.

SDH5 Depletion Enhances Radiosensitivity by Regulating p53: A New Method for Noninvasive Prediction of Radiotherapy Response

Jie Li, Gang Wu, Sihua Wang, 2019, Theranostics.

Interactions of n-Tetraalkylammonium Compounds and Biguanides with a Human Renal Organic Cation Transporter (hOCT2)

Kathleen M. Giacomini, Maya K. Leabman, K. Giacomini, 2002, Pharmaceutical Research.

Special Section – New Models in Drug Metabolism and Transport — Minireview Emerging Kidney Models to Investigate Metabolism , Transport , and Toxicity of Drugs and Xenobiotics

P. Bajaj, G. Xiao, E. Kelly, 2018 .

Positron Emission Tomography Imaging of [11C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A

Mark Muzi, Yurong Lai, Laigao Chen, 2019, Clinical pharmacology and therapeutics.

Receptor-Mediated Endocytosis and Brain Delivery of Therapeutic Biologics

G. Xiao, L. Gan, Guangqing Xiao, 2013, International journal of cell biology.

Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans

Andy Z. X. Zhu, C. Xia, M. Liao, 2018, Xenobiotica; the fate of foreign compounds in biological systems.

A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans

L. Lesko, I. Nestorov, H. Naik, 2018, Journal of Pharmacokinetics and Pharmacodynamics.

Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics

W. Humphreys, X. Chu, R. Evers, 2018, Drug Metabolism and Disposition.

Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative Proteomics

Li Wang, Carol Collins, Cornelis E. C. A. Hop, 2016, Drug Metabolism and Disposition.

Prediction of Transporter-Mediated Rosuvastatin Hepatic Uptake Clearance and Drug Interaction in Humans Using Proteomics-Informed REF Approach

S. Heyward, W. Humphreys, X. Chu, 2020, Drug Metabolism and Disposition.